Vitamin E but not St. John's wort mitigates leukopenia caused by cancer chemotherapy in rats

Translational Research

Volumn 148, Issue 6, 2006, Pages 315-324

  Branda, Richard F ^a,b   Powden, Cheryl ^a   Brooks, Elice M ^a   Yildirim, Zafer ^b   Naud, Shelly J ^b   McCormack, John J ^a,c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; MITOCHONDRIAL DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HYPERICUM PERFORATUM; LD 50; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MITOCHONDRION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; STANDARD; STATISTICAL SIGNIFICANCE; VITAMIN SUPPLEMENTATION;

EID: 33845341483     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.05.007     Document Type: Article

References (47)

1. Sparber A., Ford D., and Kvochak P.A. National Institutes of Health's Clinical Center sets new policy on use of herbal and other alternative supplements by patients enrolled in clinical trials. Cancer Invest 22 (2004) 132-137
2. Cassileth B.R., and Deng G. Complementary and alternative therapies for cancer. The Oncologist 9 (2004) 80-89
3. Burstein H.J., Gelber S., Guadagnoli E., and Weeks J. Use of alternative medicine by women with early-stage breast cancer. N Eng J Med 340 (1999) 1733-1739
4. Glass E.L., Blau R., Drosick R., Hawley D.K., and Lower E.E. Use of complementary/alternative therapies during chemotherapy for breast cancer. J Clin Oncol 22 14S (2004) 762s (abs)
5. Branda R.F., Naud S.J., Brooks E.M., Chen Z., and Muss H. Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy-induced mucositis and neutropenia. Cancer 101 (2004) 1058-1064
6. Norman H.A., Butrum R.R., Feldman E., Heber D., Nixon D., Picciano M.F., et al. The role of dietary supplements during cancer therapy. J Nutr 133 (2003) 3794S-3799S
7. Izzo A.A., and Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61 (2001) 2163-2175
8. Fugh-Berman A. Herb-drug interactions. Lancet 355 (2000) 134-138
9. Mathijssen R.H.J., Verweij J., de Bruijn P., Loos W.J., and Sparreboom A. Effects of St John's wort on irinotecan metabolism. J Natl Cancer Inst 94 (2002) 1247-1249
10. Barnes J., Anderson L.A., and Phillipson J.D. St John's wort (Hypericum perforatum L): a review of its chemistry, pharmacology and clinical properties. JPP 53 (2001) 583-600
11. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.-S., et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290 (2003) 1500-1504
12. Wang Z., Gorski J.C., Hamman M.A., Huang S.-M., Lesko L.J., and Hall S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70 (2001) 317-326
13. Wang E.-j., Barecki-Roach M., and Johnson W.W. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. JPP 56 (2004) 123-128
14. Nebel A., Schneider B.J., Baker R.K., and Kroll D.J. Potential metabolic interaction between St.John's wort and theophylline (letter). Ann Pharmacother 33 (1999) 502
15. Van Resnburg C.E.J., Joone G., and Anderson R. α Tocopherol antagonizes the multidrug-resistance-reversal activity of cyclosporine A, verapamil, GF 120918, clofazimine and B669. Cancer Lett 127 (1998) 107-112
16. Chen H.-W., Lii C.-K., Sung W.-C., and Ko Y.J. Effect of vitamin E on rat hepatic cytochrome P-450 activity. Nutr Cancer 3 (1998) 178-183
17. Brigelius-Flohě R. Vitamin E and drug metabolism. BBRC 305 (2003) 737-740
18. Dirvin H.A.A.M., van Ommen B., and van Bladeren P.J. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione-S-transferases. Chem Res Toxicol 9 (1996) 351-360
19. Marr K.A., Leisenring W., Crippa F., Slattery J.T., Corey L., Moeckh M., et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103 (2004) 1557-1559
20. Kartner N., Shales M., Riordan J.R., and Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glyocoprotein. Cancer Res 43 (1983) 4413-4419
21. Eisenhauer E.A., and Vermorken J.B. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 55 (1998) 5-30
22. Biber A., Fischer G., Romer A., and Chatterjee S.S. Oral bioavailability of hyperforin and hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31 Suppl 1 (1998) 36-43
23. Julianto T., Yuen K.H., and Noor A.M. Simple high-performance liquid chromatographic method for detemination of α-tocopherol in human plasma. J Chromat B 732 (1999) 227-321
24. Gimeno E., Castellote A.I., Lamuela-Raventǒs R.M., de la Torre-Boronat M.C., and Lǒpez-Sabater M.C. Rapid high-performance liquid chromatographic method for the simultaneous determination of retinol, α-tocopherol and β-carotene in human plasma and low-density lipoproteins. J Chromat B 758 (2001) 315-322
25. Wentworth J.M., Agostini M., Love J., Scwabe J.W., and Chatterjee V.K.K. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrin 166 (2000) R11-R16
26. Bauer S., Störmer E., Graubaum H.-J., and Roots I. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J Chromat B 765 (2001) 29-35
27. Chi J.D., and Franklin M. Measurement of hyperforin a constituent of St John's wort in plasma by high-performance liquid chromatography. J Chromat B 735 (1999) 285-288
28. Warren K.E., McCully C.M., Walsh T.J., and Balis F.M. Effects of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates. Antimicrob Agents Chemother 44 (2000) 1100-1101
29. Nicklas J.A., Brooks E.M., Hunter T.C., Single R., and Branda R.F. Development of a quantitative PCR (TaqMan) assay for relative mitochondrial DNA copy number and the common mitochondrial DNA deletion in the rat. Environ Mol Mutagen 44 (2004) 313-320
30. Chung H., Wu D., Han S.N., Gay R., Goldin B., Bronson R.E., et al. Vitamin E supplementation does not alter axoxymethane-induced colonic aberrant crypt foci formation in young or old mice. J Nutr 133 (2003) 528-532
31. Mellows G., Mistry P., Norris D., and Waterfall J. The effect of XR9576 (tariquidar), a specific P-glycoprotein inhibitor, on the pharmacokinetics of doxorubicin, paclitaxel and vincristine in the rat. Proc AACR 43 (2002) 275 (abs)
32. Branda R.F., Chen Z., Brooks E.M., Naud S.J., Trainer T.D., and McCormack J.J. Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med 140 (2002) 358-368
33. Hensrud D.D., Engle D.D., and Scheitel S.M. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 74 (1999) 443-447
34. Dy G.K., Bekele L., Hanson L.J., Furth A., Mandrekar S., Sloan J.A., et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22 (2004) 4758-4763
35. Prasad K.N., Kumar A., Kochupilai V., and Cole W.C. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Amer Coll Nutr 18 (1999) 13-25
36. Prasad K.N., Kumar B., Yan X.-D., Hanson A.J., and Cole W.C. α-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Amer Coll Nutr 22 (2003) 108-117
37. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005) 37-46
38. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. JAMA 293 (2005) 1338-1347
39. Ladas E.J., Jacobson J.S., Kennedy D.D., Teel K., Fleischauer A., and Kelly K.M. Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22 (2004) 517-528
40. Sung L., Greenberg M.L., Koren G., Tomlinson G.A., Tong A., Malkin D., et al. Vitamin E: the evidence for multiple roles in cancer. Nutr Cancer 46 (2003) 1-14
41. Argyriou A.A., Chroni E., Koutras A., Ellul J., Papapetropoulos S., Katsoulas G., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy. Neurol 64 (2005) 26-31
42. Brigelius-Flohě R., Kelly F.J., Salonen J.T., Neuzil J., Zingg J.-M., and Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr 76 (2002) 703-716
43. Cullinane C., Cutts S.M., Panousis C., and Phillips D.R. Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucl Acids Res 28 (2000) 1019-1025
44. Conklin K.A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37 (2000) 1-18
45. Breed J.G.S., Zimmerman A.N.E., Dormans J.A.M.A., and Pinedo H.M. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res 40 (1980) 2033-2038
46. Moraes C.T. What regulates mitochondrial DNA copy number in animal cells?. Trends Genet 17 (2001) 199-205
47. Lee H.-C., Yin P.-H., Lu C.-Y., Chi C.-W., and Wei Y.-H. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J 348 (2000) 425-432